Compare Stocks: URGN, LNTH, BLTE, and LQDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$169.88 +5.7%	$156.86	$64.00 ▼ $200.00	$6.84B	-1.23	190,676 shs	160,544 shs
LNTH Lantheus	$100.85 +0.0%	$103.45	$49.67 ▼ $111.86	$6.58B	-0.03	1.10 million shs	401,444 shs
LQDA Liquidia	$68.31 -2.0%	$78.86	$21.15 ▼ $93.61	$6.11B	0.53	1.75 million shs	609,823 shs
URGN Urogen Pharma	$45.22 +1.8%	$42.32	$15.86 ▼ $50.81	$2.21B	1.57	804,963 shs	241,508 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	+2.53%	+2.53%	+3.79%	+11.21%	+145.81%
LNTH Lantheus	-0.07%	-0.01%	-0.38%	-1.95%	+82.33%
LQDA Liquidia	+4.14%	-2.35%	-16.90%	+11.80%	+143.81%
URGN Urogen Pharma	+2.37%	-3.31%	+15.11%	+60.94%	+127.44%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$169.88 +5.7%	$156.86	$64.00 ▼ $200.00	$6.84B	-1.23	190,676 shs	160,544 shs
LNTH Lantheus	$100.85 +0.0%	$103.45	$49.67 ▼ $111.86	$6.58B	-0.03	1.10 million shs	401,444 shs
LQDA Liquidia	$68.31 -2.0%	$78.86	$21.15 ▼ $93.61	$6.11B	0.53	1.75 million shs	609,823 shs
URGN Urogen Pharma	$45.22 +1.8%	$42.32	$15.86 ▼ $50.81	$2.21B	1.57	804,963 shs	241,508 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	+2.53%	+2.53%	+3.79%	+11.21%	+145.81%
LNTH Lantheus	-0.07%	-0.01%	-0.38%	-1.95%	+82.33%
LQDA Liquidia	+4.14%	-2.35%	-16.90%	+11.80%	+143.81%
URGN Urogen Pharma	+2.37%	-3.31%	+15.11%	+60.94%	+127.44%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	2.67	Moderate Buy	$205.80	21.14% Upside
LNTH Lantheus	2.29	Hold	$108.11	7.20% Upside
LQDA Liquidia	2.45	Hold	$98.08	43.59% Upside
URGN Urogen Pharma	2.80	Moderate Buy	$50.38	11.40% Upside

Current Analyst Ratings Breakdown

Latest URGN, LNTH, BLTE, and LQDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	BLTE Belite Bio	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/3/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/27/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/18/2026	BLTE Belite Bio	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	LNTH Lantheus	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
8/14/2026	BLTE Belite Bio	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$201.00 ➝ $206.00
8/14/2026	BLTE Belite Bio	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	BLTE Belite Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$220.00
8/13/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C+) ➝ Hold (C)
8/13/2026	LQDA Liquidia	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$106.00
8/13/2026	LQDA Liquidia	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$62.00 ➝ $108.00

(Data available from 9/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$19.28 per share	N/A
LNTH Lantheus	$1.54B	4.27	$6.38 per share	15.80	$20.10 per share	5.02
LQDA Liquidia	$158.32M	38.62	N/A	N/A	$2.18 per share	31.33
URGN Urogen Pharma	$109.79M	20.13	N/A	N/A	($2.71) per share	-16.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$77.61M	-$2.73	N/A	186.68	N/A	N/A	-11.84%	-11.62%	11/9/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.36	18.64	N/A	17.69%	28.10%	14.35%	11/5/2026 (Estimated)
LQDA Liquidia	-$68.92M	$1.37	49.86	15.60	N/A	30.74%	149.65%	36.30%	11/2/2026 (Estimated)
URGN Urogen Pharma	-$153.49M	-$1.98	N/A	12.96	N/A	-51.73%	N/A	-43.79%	11/5/2026 (Estimated)

Latest URGN, LNTH, BLTE, and LQDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	BLTE Belite Bio	-$0.73	-$0.54	+$0.19	-$0.70	N/A	N/A
8/12/2026	Q2 2026	LQDA Liquidia	$0.7580	$0.74	-$0.0180	$0.74	$168.48 million	$171.68 million
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
8/5/2026	Q2 2026	URGN Urogen Pharma	-$0.2650	-$0.28	-$0.0150	-$0.28	$63.55 million	$72.46 million
6/30/2026	Q2 2026	BLTE Belite Bio	N/A	-$0.54	N/A	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
LQDA Liquidia	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	33.56	33.56
LNTH Lantheus	0.43	3.06	2.89
LQDA Liquidia	0.63	2.31	2.12
URGN Urogen Pharma	N/A	3.80	3.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
LNTH Lantheus	99.06%
LQDA Liquidia	64.54%
URGN Urogen Pharma	91.29%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
LNTH Lantheus	1.70%
LQDA Liquidia	25.60%
URGN Urogen Pharma	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	10	40.27 million	34.92 million	Not Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable
LQDA Liquidia	50	89.51 million	66.60 million	Optionable
URGN Urogen Pharma	200	48.88 million	46.54 million	Optionable

URGN, LNTH, BLTE, and LQDA Headlines

Recent News About These Companies

UroGen Pharma to Present at Upcoming Investor Conferences

September 2 at 8:00 AM | globenewswire.com

BlackRock Inc. Purchases Shares of 3,201,461 Urogen Pharma $URGN

August 30, 2026 | marketbeat.com

Deutsche Bank AG Takes $1.90 Million Position in Urogen Pharma $URGN

August 29, 2026 | marketbeat.com

Palo Alto Investors LP Purchases New Shares in Urogen Pharma $URGN

August 28, 2026 | marketbeat.com

Jefferies Financial Group Inc. Buys New Position in Urogen Pharma $URGN

August 28, 2026 | marketbeat.com

Coastal Bridge Advisors LLC Invests $1.36 Million in Urogen Pharma $URGN

August 28, 2026 | marketbeat.com

Elmind Capital LP Invests $4.42 Billion in Urogen Pharma $URGN

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Buys New Position in Urogen Pharma $URGN

August 26, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Acquires New Position in Urogen Pharma $URGN

August 25, 2026 | marketbeat.com

Mark Schoenberg Sells 60,677 Shares of Urogen Pharma (NASDAQ:URGN) Stock

August 25, 2026 | insidertrades.com

Urogen Pharma (NASDAQ:URGN) Insider Sells $2,854,852.85 in Stock

August 24, 2026 | marketbeat.com

Urogen Pharma (NASDAQ:URGN) Given Consensus Recommendation of "Moderate Buy" by Analysts

August 23, 2026 | americanbankingnews.com

Urogen Pharma (NASDAQ:URGN) Given Average Rating of "Moderate Buy" by Brokerages

August 23, 2026 | marketbeat.com

Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet

August 21, 2026 | zacks.com

UroGen Pharma Earnings Call Highlights ZUSDURI Surge

August 20, 2026 | tipranks.com

UroGen Signs Investment, Collaboration Agreements With IntraGel for Access to Sustained-Release Platform

August 20, 2026 | finance.yahoo.com

UroGen Pharma inks licensing deal with IntraGel Therapeutics

August 20, 2026 | thepharmaletter.comT

UroGen Pharma Ltd.: UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology ...

August 20, 2026 | finanznachrichten.de

UroGen to invest up to $7M in IntraGel as part of an option agreement

August 20, 2026 | msn.com

UroGen Pharma Expands Oncology Pipeline With SRGel Partnership

August 20, 2026 | tipranks.com

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

August 20, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN, LNTH, BLTE, and LQDA Company Descriptions

Belite Bio NASDAQ:BLTE

$169.88 +9.22 (+5.74%)

As of 03:40 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Lantheus NASDAQ:LNTH

$100.85 +0.04 (+0.04%)

As of 03:38 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Liquidia NASDAQ:LQDA

$68.31 -1.37 (-1.97%)

As of 03:39 PM Eastern

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Urogen Pharma NASDAQ:URGN

$45.22 +0.80 (+1.80%)

As of 03:39 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest URGN, LNTH, BLTE, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest URGN, LNTH, BLTE, and LQDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

URGN, LNTH, BLTE, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN, LNTH, BLTE, and LQDA Company Descriptions

Belite Bio NASDAQ:BLTE

Lantheus NASDAQ:LNTH

Liquidia NASDAQ:LQDA

Urogen Pharma NASDAQ:URGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest URGN, LNTH, BLTE, and LQDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest URGN, LNTH, BLTE, and LQDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

URGN, LNTH, BLTE, and LQDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

URGN, LNTH, BLTE, and LQDA Company Descriptions

Belite Bio NASDAQ:BLTE

Lantheus NASDAQ:LNTH

Liquidia NASDAQ:LQDA

Urogen Pharma NASDAQ:URGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools